[Relationship between tissue concentrations of 5-FU and degeneration of tissues after UFT administration in patients with bladder tumor]. 1993

M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
Dept. of Urology, Sakai Municipal Hospital.

The relationship between the 5-FU concentration and tissue degeneration was studied in the bladder tumor tissue after UFT administration. In 12 patients with bladder tumor, UFT 400 mg/day was administered orally for about 2 weeks before TUR, and tegaful, 5-FU and uracil concentrations were examined in the blood and the tumor tissue taken about 6 hours after the last administration. Tumor tissue was also taken before and after the UFT administration, and the degree of cell degeneration due to UFT administration were evaluated by light and electron microscopy. The 5-FU concentration was significantly higher in the tumor tissue (0.078 +/- 0.091 microgram/g) than in the serum (0.017 +/- 0.010 microgram/ml). Signs of degeneration were observed in tumor cells after UFT administration in all 6 patients in whom the tumor tissue 5-FU concentration was 0.046 microgram/g or higher. Mitosis was not increased after UFT administration in any of the 12 patients.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
October 1986, Hinyokika kiyo. Acta urologica Japonica,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
February 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
January 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
August 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
March 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
M Takeyama, and M Honjoh, and N Ohnishi, and Y Ishikawa, and H Sakaguchi, and J Hanai
April 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!